# Cortexyme

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cortexyme

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.cortexyme.com
- Total disclosed funding: $93M
- Latest round: Series B (May 23, 2018)
- Investors on record: 11

## About

Founded in 2012 and based in California, US, Cortexyme, Inc. is a biopharmaceutical company that researches and develops treatments for Alzheimer's disease. They develop treatments for altering the course of Alzheimer's and other neurological diseases by targeting a specific pathogen tied to neurodegeneration.

## Funding rounds

- Series B, May 23, 2018, $84M — Hong Shan, Vulcan, Pfizer Inc., Takeda Ventures, Lamond Capital Partners, Dolby Family Ventures, Breakout Ventures, Huizenga Group, Epiq Capital, RSL Investments, Verily Life Sciences LLC
- Series A, Dec 22, 2015, $7.9M — Pfizer Inc., Takeda Ventures, Dolby Family Ventures
- Seed, Oct 6, 2014, $1M — Dolby Family Ventures

## Investors

- Dolby Family Ventures (https://capitalatlas.ai/funds/dolby-family-ventures) — Seed, Series A, Series B
- Pfizer Inc. — Series A, Series B
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series A, Series B
- Hong Shan — Series B
- Vulcan (https://capitalatlas.ai/funds/vulcan) — Series B
- Lamond Capital Partners — Series B
- Breakout Ventures (https://capitalatlas.ai/funds/breakout-ventures) — Series B
- Huizenga Group — Series B
- Epiq Capital (https://capitalatlas.ai/funds/epiq-capital) — Series B
- RSL Investments — Series B
- Verily Life Sciences LLC — Series B